论文部分内容阅读
[目的]在体外采用自然实验体系研究肺癌患者系统血液快速固有免疫反应的变化。[方法]全血细胞自然实验管(0.2ml全血细胞悬液,0.2ml5×106/mlS180细胞悬液,0.3ml血浆)和全血自然对照组(0.2ml全血细胞悬液,0.2ml生理盐水,0.3ml血浆),均37℃温育1h,用流式细胞仪测定红细胞CD59和白细胞的CD25分子的表达。[结果]肿瘤细胞能激活全血细胞,增强正常人和肺癌患者的CD59和CD25分子的表达,但CD59表达量正常人实验组(33.04±2.93)明显高于正常人对照组(29.96±5.40)、肺癌患者实验组(29.60±6.48)和肺癌患者对照组(28.36±4.69)(P<0.01);CD25表达量正常人实验组(7.29±3.00)明显高于正常人对照组(5.28±1.78),肺癌患者实验组CD25表达量(5.99±1.96)和肺癌患者对照组(4.60±1.78)(P<0.01)。[结论]在体外肿瘤细胞能激活系统血液快速固有免疫反应,但肺癌患者抗肿瘤的系统血液快速固有免疫反应水平明显低于正常人抗肿瘤的系统血液快速固有免疫反应水平。
[Objective] The purpose of this study was to investigate the changes of rapid innate immune response in patients with lung cancer using natural experimental system in vitro. [Method] The whole blood cell natural experimental tube (0.2 ml whole blood cell suspension, 0.2 ml 5 × 106 / ml S180 cell suspension and 0.3 ml plasma) and the whole blood natural control group (0.2 ml whole blood cell suspension, 0.2 ml normal saline, 0.3 ml plasma) were incubated at 37 ℃ for 1 h, the expression of CD25 and CD25 on erythrocytes and leukocytes were measured by flow cytometry. [Results] The tumor cells could activate whole blood cells and enhance the expressions of CD59 and CD25 in normal and lung cancer patients. However, the expression of CD59 in the normal group was significantly higher than that in the normal control group (33.04 ± 2.93, 29.96 ± 5.40) (29.60 ± 6.48) and lung cancer control group (28.36 ± 4.69) (P <0.01). The level of CD25 expression in normal control group (7.29 ± 3.00) was significantly higher than that in control group (5.28 ± 1.78) The expression of CD25 in experimental lung cancer patients (5.99 ± 1.96) and lung cancer control group (4.60 ± 1.78) (P <0.01). [Conclusion] The in vitro tumor cells can activate the systemic rapid immune response. However, the anti-tumor systemic blood fasting innate immune response in lung cancer patients is significantly lower than that of the normal human anti-tumor systemic blood fasting innate immune response.